The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-Controlled, Double-Blind, Parallel-Group, Adaptive Trial
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Rexmyelocel T (Primary)
- Indications Peripheral ischaemia
- Focus Registrational; Therapeutic Use
- Sponsors Rexgenero
- 07 Sep 2018 Last checked against ClinicalTrials.gov record.
- 28 Aug 2018 Planned End Date changed from 30 Dec 2019 to 31 Oct 2021.
- 28 Aug 2018 Planned primary completion date changed from 30 Dec 2018 to 31 Oct 2020.